14.3 Surveillance and Tracking of Antimicrobial Resistance Patterns

Surveillance and Tracking of Antimicrobial Resistance Patterns

The dissemination of multidrug-resistant organisms (MDROs) represents an urgent global public health threat compromising modern medical care, including cancer chemotherapy, solid organ transplantation, and complex surgical procedures. Antimicrobial stewardship programs must collaborate closely with clinical microbiology laboratories and infection prevention and control (IPC) teams to track local, regional, and national resistance patterns, rapidly detect nosocomial outbreaks, and interrupt transmission chains.

---

The Multi-Tiered Architecture of Resistance Surveillance

Surveillance of antimicrobial resistance (AMR) relies on interconnected public health reporting networks operating across local, regional, national, and international tiers:

                      TIERED AMR SURVEILLANCE ECOSYSTEM

 ┌─────────────────────────────────────────────────────────────────────────────┐
 │ GLOBAL TIER: WHO GLASS (Global Antimicrobial Resistance Surveillance System)│
 ├─────────────────────────────────────────────────────────────────────────────┤
 │ NATIONAL TIER: CDC AR Threats Report, NHSN AR Option, NARMS (Enteric)       │
 ├─────────────────────────────────────────────────────────────────────────────┤
 │ REGIONAL TIER: CDC AR Lab Network (7 Regional Labs + Specialized Testing)   │
 ├─────────────────────────────────────────────────────────────────────────────┤
 │ LOCAL TIER: Hospital LIS, Infection Prevention Dashboards, Annual Antibiogram│
 └─────────────────────────────────────────────────────────────────────────────┘

1. Local Facility Surveillance

• Hospital Laboratory Information Systems (LIS): Provides real-time alert systems flagging critical multi-drug resistant phenotypes (e.g., novel carbapenem resistance, vancomycin-resistant S. aureus [VRSA], or Candida auris isolates) to trigger prompt patient isolation.
• NHSN Antimicrobial Resistance (AR) Option: Enables hospitals to electronically submit patient-level antimicrobial susceptibility test (AST) data directly from laboratory analyzers, generating local, regional, and national resistance benchmarks.

2. Regional Public Health Surveillance: The CDC AR Lab Network

Established in 2016, the CDC Antimicrobial Resistance Laboratory Network (AR Lab Network) consists of seven regional public health laboratories supported by the CDC and local state public health labs. The network provides specialized, high-tier testing unavailable in most hospital laboratories:

• Confirmatory molecular testing for carbapenemase genes (KPC, NDM, OXA-48, VIM, IMP).
• Rectal colonization screening for carbapenemase-producing organisms (CPO).
• Identification and susceptibility testing for Candida auris and antifungal-resistant molds.
• Whole-genome sequencing of outbreak clusters to track inter-facility transmission.

3. National and Global Surveillance

• CDC AR Threats Report: Categorizes antimicrobial-resistant pathogens into Urgent, Serious, and Concerning threat levels based on clinical impact, economic burden, incidence, 10-year projection, transmissibility, and treatability.
• National Antimicrobial Resistance Monitoring System (NARMS): Collaboration between CDC, FDA, and USDA tracking resistance in foodborne and enteric bacteria (Salmonella, Campylobacter, Shigella, and E. coli).
• WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS): Aggregates worldwide surveillance data to monitor global trends and track international resistance dissemination.

---

Critical Resistant Pathogens and CDC Threat Classifications

                      CDC ANTIMICROBIAL RESISTANCE THREAT TIERS

     URGENT THREATS                                  SERIOUS THREATS
  ┌────────────────────────────────────┐          ┌────────────────────────────────────┐
  │ • Carbapenem-Resistant             │          │ • DTR / MDR Pseudomonas aeruginosa │
  │   Enterobacterales (CRE)           │          │ • Carbapenem-Resistant Acinetobacter│
  │ • Candida auris                    │          │ • Methicillin-Resistant S. aureus  │
  │ • Clostridioides difficile         │          │ • Vancomycin-Resistant Enterococcus│
  │ • Drug-Resistant N. gonorrhoeae    │          │ • ESBL-Producing Enterobacterales  │
  └────────────────────────────────────┘          │ • Multidrug-Resistant Tuberculosis │
                                                  └────────────────────────────────────┘

CDC Urgent Threats (Immediate Public Health Action Mandated)

1. Carbapenem-Resistant Enterobacterales (CRE)

• Phenotypic Definition: Enterobacterales (most commonly Klebsiella pneumoniae, Escherichia coli, and Enterobacter cloacae complex) demonstrating resistance to at least one carbapenem (meropenem, imipenem, doripenem, or ertapenem) or documented production of a carbapenemase enzyme.
• Molecular Classification (Ambler Classes):
  • Class A (Serine Carbapenemases): Dominated by Klebsiella pneumoniae carbapenemase (KPC). Inhibited by avibactam, vaborbactam, and relebactam. First-line agents: ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-cilastatin-relebactam.
  • Class B (Metallo-Beta-Lactamases [MBL]): Includes New Delhi metallo-beta-lactamase (NDM), Verona integron-encoded metallo-beta-lactamase (VIM), and IMP. MBLs utilize zinc ions at their active catalytic site, enabling hydrolysis of all penicillins, cephalosporins, and carbapenems, while sparing monobactams (aztreonam). Importantly, MBLs are NOT inhibited by avibactam, vaborbactam, or relebactam. However, clinical MBL-producing isolates almost universally co-produce serine beta-lactamases (ESBLs or AmpC) that hydrolyze aztreonam. Therefore, definitive first-line regimens require ceftazidime-avibactam PLUS aztreonam (avibactam protects aztreonam from co-expressed serine enzymes while aztreonam resists MBL hydrolysis) or cefiderocol.
  • Class D (Oxacillinases): Dominated by OXA-48-like enzymes. Frequently hydrolyze penicillins and carbapenems while sparing third- and fourth-generation cephalosporins, but co-expressed ESBLs confer broad cephalosporin resistance. Inhibited by avibactam (ceftazidime-avibactam is first-line), but NOT inhibited by vaborbactam or relebactam.
• Non-Carbapenemase-Producing CRE (Non-CP-CRE): Mediated by hyperexpression of AmpC or ESBL beta-lactamases combined with structural outer membrane porin mutations (loss of OmpK35/OmpK36 in K. pneumoniae or OmpF/OmpC in E. coli), severely restricting carbapenem periplasmic entry.

2. Candida auris

• Clinical Significance: An emerging multi-drug resistant fungal pathogen characterized by aggressive healthcare transmission, persistent cutaneous colonization (axillae and groins), and prolonged environmental persistence on plastic, vinyl, and stainless steel surfaces.
• Resistance Profile: $> 90\%$ of isolates are resistant to fluconazole; up to $30\%$ display resistance to amphotericin B; and $5\%$ exhibit echinocandin resistance (pan-resistant strains have been documented, driven by FKS1 hot-spot mutations).
• Laboratory Identification Traps: Frequently misidentified by legacy automated biochemical platforms (e.g., VITEK 2 older software versions misidentify C. auris as Candida haemulonii; API 20C AUX misidentifies it as Rhodotorula glutinis). Definitive confirmation requires matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) or molecular sequencing.
• Infection Control Mandate: Requires strict Contact Precautions in single-occupancy rooms and environmental decontamination using EPA-registered disinfectants with specific activity against C. auris (EPA List P).

3. Clostridioides difficile

Spore-forming anaerobic bacillus that drives healthcare-associated diarrhea and pseudomembranous colitis, fueled by systemic antibiotic collateral damage to the protective gut microbiome.

4. Drug-Resistant Neisseria gonorrhoeae

Strains exhibiting high-level resistance to ceftriaxone, cefixime, ciprofloxacin, and azithromycin, threatening the viability of standard single-dose empirical regimens.

---

CDC Serious Threats (High Priority Inpatient Pathogens)

1. Difficult-to-Treat Resistance Pseudomonas aeruginosa (DTR-P. aeruginosa)

• Definition: Non-susceptible to all first-line anti-pseudomonal beta-lactams and fluoroquinolones: piperacillin-tazobactam, cefepime, ceftazidime, meropenem, imipenem-cilastatin, and ciprofloxacin/levofloxacin.
• Resistance Mechanisms: Unlike Enterobacterales, resistance in P. aeruginosa is primarily driven by chromosomal, non-carbapenemase mechanisms:
  • Loss or down-regulation of the OprD outer membrane porin (specifically prevents carbapenem entry).
  • Derepression of chromosomal AmpC cephalosporinase.
  • Upregulation of active multidrug efflux pump systems (MexAB-OprM, MexCD-OprJ, MexXY-OprM).
  • Penicillin-binding protein (PBP) mutations.
• Targeted Therapies: Ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-cilastatin-relebactam, or cefiderocol.

2. Carbapenem-Resistant Acinetobacter baumannii (CRAB)

• High environmental stability; survives for months on dry surfaces. Resistance is mediated by Class D carbapenem-hydrolyzing oxacillinases (OXA-23, OXA-24/40, OXA-58) combined with porin deficiencies and efflux pump hyper-expression.
• Modern First-Line Regimen: Sulbactam-durlobactam (durlobactam is a novel broad-spectrum diazabicyclooctane beta-lactamase inhibitor that specifically inhibits Class D oxacillinases, restoring sulbactam's direct PBP1/PBP3-mediated killing of Acinetobacter).

3. Methicillin-Resistant Staphylococcus aureus (MRSA)

• Mediated by the chromosomal acquisition of the staphylococcal cassette chromosome mec (SCCmec) carrying the mecA or mecC gene, which encodes PBP2a—an altered penicillin-binding protein with ultra-low binding affinity for almost all beta-lactams (with the exception of fifth-generation cephalosporins: ceftaroline and ceftobiprole).

4. Vancomycin-Resistant Enterococcus (VRE)

• Primarily Enterococcus faecium ($> 80\%$ vancomycin-resistant in US ICUs) rather than Enterococcus faecalis ($< 10\%$ resistant).
• Mechanisms: Replacement of the terminal D-alanyl-D-alanine (D-Ala-D-Ala) dipeptide of cell-wall peptidoglycan precursors with D-alanyl-D-lactate (D-Ala-D-Lac), reducing vancomycin binding affinity by 1,000-fold.
  • vanA Phenotype: Inducible, high-level resistance to both vancomycin and teicoplanin; plasmid-borne transposon (Tn1546).
  • vanB Phenotype: Inducible resistance to vancomycin, but retains in vitro susceptibility to teicoplanin; chromosomal or transmissible.

5. Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacterales

• Enzymes that hydrolyze penicillins, extended-spectrum cephalosporins (ceftriaxone, cefotaxime, ceftazidime), and aztreonam, but do not hydrolyze carbapenems and are inhibited by beta-lactamase inhibitors.
• Dominated globally by CTX-M enzymes (specifically CTX-M-15).
• Definitive Treatment for Invasive Infections: Carbapenems (meropenem, ertapenem) remain the standard of care for severe bloodstream infections based on the landmark MERINO randomized trial, which demonstrated that piperacillin-tazobactam was non-inferiority failed compared to meropenem (30-day mortality $12.3\%$ with piperacillin-tazobactam vs $3.7\%$ with meropenem).

---

Molecular Epidemiology and Outbreak Investigation

When a cluster of resistant pathogens is identified, infection preventionists and stewardship teams utilize molecular epidemiology to differentiate between clonal spread and horizontal gene transfer:

                      DISSEMINATION MECHANISMS IN OUTBREAKS

     CLONAL TRANSMISSION (VERTICAL)                 HORIZONTAL GENE TRANSFER (LATERAL)
  ┌────────────────────────────────────┐         ┌────────────────────────────────────┐
  │ • Single bacterial clone spreads   │         │ • Distinct bacterial species share │
  │   from patient to patient via      │         │   a mobile resistance plasmid      │
  │   contaminated hands or devices    │         │ • Example: IncFII plasmid carrying │
  │ • Identical ST and ≤ 3-5 SNVs      │         │   blaKPC shared by K. pneumoniae,  │
  │ • Control: Hand hygiene, contact   │         │   E. coli, and Enterobacter cloacae│
  │   precautions, environmental clean │         │ • Control: Antimicrobial pressure  │
  └────────────────────────────────────┘         └────────────────────────────────────┘

Molecular Typing Methodologies

1. Pulsed-Field Gel Electrophoresis (PFGE):
   • Historical standard; uses macro-restriction enzymes to cut genomic DNA into large fragments separated by alternating electrical fields.
   • Limitations: Highly labor-intensive, poor inter-laboratory reproducibility, subjective interpretation (Tenover criteria: isolates differing by $\le 3$ bands are considered clonally related).
2. Multilocus Sequence Typing (MLST):
   • Sequences internal fragments of 7 conserved housekeeping genes to assign an allelic profile and Sequence Type (ST) (e.g., E. coli ST131, K. pneumoniae ST258, S. aureus ST8 [USA300]).
   • Limitations: Sufficient for global evolutionary phylogenetics, but lacks adequate discriminatory power to resolve acute hospital transmission events among isolates sharing the same ST.
3. Whole-Genome Sequencing (WGS):
   • Current gold standard for outbreak investigation. Analyzes the complete nucleotide sequence of the bacterial chromosome and extrachromosomal plasmids.
   • Core-Genome MLST (cgMLST): Analyzes thousands of conserved core genes simultaneously.
   • Single-Nucleotide Variant (SNV) Analysis: Identifies single base-pair mutations across the genome. In acute hospital outbreak investigations, isolates differing by $\le 3$ to 5 SNVs generally confirm direct patient-to-patient transmission chains.
   • Plasmid Reconstruction and Insertion Sequence Profiling: Identifies whether diverse species share identical mobile genetic elements (e.g., transposon Tn4401 carrying blaKPC), confirming lateral plasmid transfer across different host species.